Antibiotics Partnering Terms and Agreements(2) -





IPR Bundle ButtonPublished: June 2014 | Version: 3 | Pages: 392

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in antibiotics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Antibiotics partnering contract documents
  • Top antibiotics deals by value

 

The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

 

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

 

  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

                                

This report contains over 150 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

For example, analyzing actual company deals and agreements allows assessment of the following:

 

  • What is actually granted by the agreement to the partner company?

                

  • What exclusivity is granted?

 

  • What are the precise rights granted or optioned?

 

  • What is the payment structure for the deal?

 

  • How aresalesand payments audited?

 

  • What is the deal term?

 

  • How are the key terms of the agreement defined?

 

  • How are IPRs handled and owned?

 

  • Who is responsible for commercialization?

 

  • Who is responsible for development, supply, and manufacture?

 

  • How is confidentiality and publication managed?

 

  • How are disputes to be resolved?

 

  • Under what conditions can the deal be terminated?

 

  • What happens when there is a change of ownership?

 

  • What sublicensing and subcontracting provisions have been agreed?

 

  • Which boilerplate clauses does the company insist upon?

 

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

 

  • Which jurisdiction does the company insist upon for agreement law?

 

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading antibiotics deals since 2009. Deals are listed by headline value, signed by big pharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal announced along with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009 organized by antibiotics technology focus. The chapter includes deals listed by antibiotics and broken down into individual type of antibiotics- aminoglycosides, cephalosporin, clindamycin, macrolides, metronidazole, penicillin, quinolones and tetracycline. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2009.

 

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z , stage of development, deal type and therapy focus, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope

                            

Antibiotics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

 

                                             

Antibiotics Partnering Terms and Agreements includes:

                                                        

  • Trends in antibiotics dealmaking in the biopharma industry since 2009
  • Analysis of antibiotics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life antibiotics deals
  • Access to over 150 antibiotics contract documents
  • The leading antibody deals by value since 2009
  • Most active antibiotics dealmakers since 2007
  • The leading antibiotics partnering resources

 

 

In Antibiotics Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Executive Summary
Chapter 1 – Introduction
 

Chapter 2 – Trends in antibiotics dealmaking 

2.1. Introduction

2.2. Antibiotics partnering over the years

2.3. Big pharma antibiotics dealmaking activity

2.4. Big biotech antibiotics dealmaking activity

2.5. Most active in antibiotics partnering

2.6. Antibiotics partnering by deal type

2.7. Antibiotics partnering by disease type

2.8. Partnering by antibiotics technology type

2.9. Partnering by antibiotics stage of development

2.10. Average deal terms for antibiotics partnering

2.10.1 Antibiotics headline values

2.10.2 Antibiotics upfront payments

2.10.3 Antibiotics milestone payments

2.10.4 Antibiotics royalty rates

2.11. The anatomy of antibiotics partnering

2.12. The anatomy of an antibiotics deal

2.12. a. Case study 1: Calixa Therapeutics & Astellas –May 24 2009

2.12.b. Case study 2: Advanced Life Sciences & Wyeth- Oct 1 2008

2.12.c. Case study 3: Astellas & Optimer Pharmaceuticals- Feb 7 2011

Chapter 3 – Leading antibiotics deals 

3.1. Introduction

3.2. Top antibiotics deals by value

Chapter 4 – Big pharma antibiotics deals 

4.1. Introduction

4.2. How to use big pharma antibiotics partnering deals

4.3. Big pharma antibiotics partnering company profiles

Abbott

Actavis

Astellas

AstraZeneca

Bayer

Eli Lilly

Forest Laboratories

Galderma

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Novartis

Pfizer

Roche

Sanofi

Shionogi

Teva

Valeant

Warner Chilcott

Chapter 5 – Big biotech antibiotics deals 

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech antibiotics partnering company profiles

Biocon

Cubist

Emergent BioSolutions

Galapagos

Optimer

Swedish Orphan Biovitrum

The Medicines Company

ViroPharma

Chapter 6 – Antibiotics partnering contracts directory 

6.1. Introduction

6.2. Company A-Z

Achaogen

Anacor Pharmaceuticals

ARK Diagnostics

Astellas Pharma

Basilea Pharmaceutica

Bayer

Biocon

Biomedical Advanced Research and Development Authority

Calixa Therapeutics

Colorado State University

Cornerstone Therapeutics

Cubist Pharmaceuticals

CUBRC

Defense Threat Reduction Agency

Department of Health and Human Services

Dipexium Pharmaceuticals

Enanta Pharmaceuticals

Genzyme

GlaxoSmithKline

Intrexon

Melinta Therapeutics

National Institute of Allergy and Infectious Diseases

Optimer Pharmaceuticals

Oragenics

Oscient Pharmaceuticals

Patheon

Polypeptide Laboratory

Prev AbR

RRD International

Sanofi

Synthetic Biologics

Tetraphase Pharmaceuticals

Teva Pharmaceutical Industries

Texas A&M University

The Regents of the University of California

Trius Therapeutics

University of California Berkeley

University of Florida Research Foundation

University of Washington

Viropharma

6.3. By deal type

Asset purchase

Co-development

Collaborative R&D

Contract service

Co-promotion

Development

Distribution

Equity purchase

Grant

Licensing

Manufacturing

Manufacturing - OEM

Marketing

Option

Research

Settlement

Supply

Termination

6.4. By stage of development

Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

6.5. By therapy area

Dental

Dermatology

Gastrointestinal

Infectives

Pediatrics

Respiratory

Chapter 7 – Antibiotics dealmaking by technology type 

7.1. Introduction

7.2. Deals by antibiotics type

Antibiotics

 

Appendices 

Appendix 1- Antibiotics deals directory by company A-Z

Appendix 2- Antibiotics deals directory by stage of development

Appendix 3- Antibiotics deals directory by deal type

Appendix 4- Antibiotics deals directory by therapy area

Appendix 5 – Antibiotics partnering resource center

Online antibiotics partnering

Appendix 6 – Antibiotics partnering events

Further reading on antibiotics dealmaking

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form – Reports

 

 Table of figures 

 

Figure 1: Antibiotics partnering since 2009

Figure 2: Big pharma – top 50 – antibiotics deals 2009-2014

Figure 3: Big pharma antibiotics deal frequency – 2009 to 2014

Figure 4: Big biotech – top 50 – antibiotics deals 2009-2014

Figure 5: Big biotech antibiotics deal frequency – 2009 to 2014

Figure 6: Active antibiotics dealmaking activity– 2009 to 2014

Figure 7: Antibiotics partnering by deal type since 2009

Figure 8: Antibiotics partnering by disease type since 2009

Figure 9: Antibiotics partnering by technology type since 2009

Figure 10: Antibiotics partnering by stage of development type

Figure 11: Antibiotics deals with a headline value

Figure 12: Antibiotics deal headline value distribution, US$million – discovery stage

Figure 13: Antibiotics deal headline value distribution, US$million – preclinical stage

Figure 14: Antibiotics deal headline value distribution, US$million – phase I stage

Figure 15: Antibiotics deal headline value distribution, US$million – phase II stage

Figure 16: Antibiotics deal headline value distribution, US$million – phase III stage

Figure 17: Antibiotics deal headline value distribution, US$million – regulatory stage

Figure 18: Antibiotics deal headline value distribution, US$million – marketed stage

Figure 19: Summary median headline value by stage of development, 2009-2014

Figure 20: Antibiotics deals with upfront payment values

Figure 21: Antibiotics deal upfront payment distribution, US$million – discovery stage

Figure 22: Antibiotics deal upfront payment distribution, US$million – preclinical stage

Figure 23: Antibiotics deal upfront payment distribution, US$million – phase I stage

Figure 24: Antibiotics deal upfront payment distribution, US$million – phase II stage

Figure 25: Antibiotics deal upfront payment distribution, US$million – phase III stage

Figure 26: Antibiotics deal upfront payment distribution, US$million – regulatory stage

Figure 27: Antibiotics deal upfront payment distribution, US$million – marketed stage

Figure 28: Summary median upfront payments by stage of development, 2009-2014

Figure 29: Antibiotics deals with milestone payments

Figure 30: Antibiotics deal milestone distribution, US$million – discovery stage

Figure 31: Antibiotics deal milestone distribution, US$million – preclinical stage

Figure 32: Antibiotics deal milestone distribution, US$million – phase I stage

Figure 33: Antibiotics deal milestone distribution, US$million – phase II stage

Figure 34: Antibiotics deal milestone distribution, US$million – phase III stage

Figure 35: Antibiotics deal milestone distribution, US$million – regulatory stage

Figure 36: Antibiotics deal milestone distribution, US$million – marketed stage

Figure 37: Antibiotics deals with royalty rates, %

Figure 38: Antibiotics deal royalty rate distribution, US$million – discovery stage

Figure 39: Antibiotics deal royalty rate distribution, US$million – preclinical stage

Figure 40: Antibiotics deal royalty rate distribution, US$million – phase I stage

Figure 41: Antibiotics deal royalty rate distribution, US$million – phase II stage

Figure 42: Antibiotics deal royalty rate distribution, US$million – phase III stage

Figure 43: Antibiotics deal royalty rate distribution, US$million – regulatory stage

Figure 44: Antibiotics deal royalty rate distribution, US$million – marketed stage

Figure 45: Summary median royalty rate by stage of development, 2009-2014

Figure 46: Components of the typical antibiotics deal structure

Figure 47: Top antibiotics deals by value since 2009

Figure 48: Online partnering resources

Figure 49: Forthcoming partnering events